Our work, collectively suggests that UBE2T enhanced MAPK/ERK activation, while MAPK/ERK inhibition reduced nuclear β‐catenin expression and subsequent EMT in UBE2T‐overexpressing HCC cells, a notion also supported by other studies in the regulation of β‐catenin degradation, localization, and cancer progression [81, 82, 83]. The gene discussed is UBE2T; the disease is hepatocellular carcinoma.